Data on this page show the responses of all individuals who received a JYNNEOS mpox (monkeypox) vaccine administered via intradermal* injection and completed an AusVaxSafety survey sent on day 7 after vaccination. These data provide you with a profile of what to expect in the days following your mpox vaccination and can assist when planning for your mpox vaccination. Data on this page will be updated fortnightly.

 

*Intradermal vaccine administration uses a short needle to inject a 0.1 mL dose of the JYNNEOS mpox vaccine into the space between the two outer layers (epidermis and dermis) of the skin.

AusVaxSafety's active vaccine safety surveillance system complements the Therapeutic Goods Administration's (TGA) safety surveillance activities. Find out more about how the TGA monitors the safety of vaccines and how you can report side effects on the TGA website.

Links to further information on mpox vaccines are available below:

AusVaxSafety will continue to closely monitor the safety data of mpox vaccines in use in Australia in conjunction with the TGA, the Department of Health and Aged Care and state and territory health departments.

Last updated January 2023